icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
 		Back grey_arrow_rt.gif
 
 
 
PrEP at CROI 2020
 
 
 
  • CROI: There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20)
     
  • CROI: Use of an HIV Prediction Model to Evaluate PrEP Coverage in a Large Healthcare System - (05/19/20)
     
  • CROI: Implementation of On-Demand PrEP in a Large Integrated Healthcare System - (05/19/20)
     
  • CROI: Non-Daily Use of HIV Preexposure Prophylaxis in a Large Online Sample in the U.S. - (05/19/20)
     
    • CROI: HIV-1 Drug Resistance in the DISCOVER Pre-exposure Prophylaxis Trial - (04/09/20)
     
    CROI: ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES -(04/08/20)
     
    Longer Term Efficacy and Safety of F/TAF and F/TDF For HIV PrEP: DISCOVER Trial Week 96 Results - (03/11/20)
     
    IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS - (03/16/20)
     
    DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants - (03/11/20)
     
    DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY (03/13/20)
     
    WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)
     
    FTC/TAF + BIC Postexposure Prophylaxis Protects Macaques Against Rectal SHIV Infection - (03/11/20)
     
    F/TAF and F/TDF Efficacy and Safety as PrEP for 96 Weeks - (03/11/20)
     
    CROI: Results from a PrEP Demonstration Project for At-Risk Cisgender Women in the US - PrEP/PEP at CROI - (04/04/20)